<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467621</url>
  </required_header>
  <id_info>
    <org_study_id>RH-ITA-006</org_study_id>
    <nct_id>NCT02467621</nct_id>
  </id_info>
  <brief_title>Stress Ulcer Prophylaxis in the Intensive Care Unit</brief_title>
  <acronym>SUP-ICU</acronym>
  <official_title>Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Morten Hylander Møller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Scandinavian Critical Care Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stress ulcer prophylaxis (SUP) is standard of care in the intensive care unit (ICU), however
      the quantity and quality of evidence is low and potential harm has been reported.

      The aim of the SUP-ICU trial is to asses the overall benefits and harms of SUP with proton
      pump inhibitor in adult critically ill patients in the ICU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critically ill patients in the ICU are at risk of stress related gastrointestinal (GI)
      bleeding, and SUP is recommended. However, the quantity and quality of evidence supporting
      SUP is low and has been questioned. Furthermore studies have shown that proton pump
      inhibitors (PPIs) may increase the risk of pneumonia, clostridium difficile infection and
      acute myocardial ischemia. The aim of the SUP-ICU trial is to assess the benefits and harms
      of SUP with PPI in adult critically ill patients in the ICU.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">January 21, 2018</completion_date>
  <primary_completion_date type="Actual">October 22, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Landmark mortality 90-days after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinically important GI bleeding, pneumonia, clostridium difficile infection or acute myocardial ischemia</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
    <description>Composite outcome of the proportion of patients with one or more of the mentioned conditions in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinically important GI bleeding</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
    <description>Proportion of patients with one or more episodes of clinically important GI bleeding in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with one or more infectious adverse events</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
    <description>Proportion of patients with one or more episodes of pneumonia or clostridium difficile infection in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Landmark mortality 1 year after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive without organ support</measure>
    <time_frame>Within 90 days</time_frame>
    <description>Percentage of days alive and free from mechanical ventilation, circulatory support and renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse reactions</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
    <description>Serious adverse reactions are: anaphylactic reactions, agranulocytosis, pancytopenia, acute hepatic failure, Steven Johnsons Syndrome and toxic epidermal necrolysis, interstitial nephritis and angioedema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A health economic analysis</measure>
    <time_frame>90 days</time_frame>
    <description>The analytic details will be based on the results of the trial and specified (cost-benefit vs cost-minimisation analyses).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3350</enrollment>
  <condition>Gastrointestinal Bleeding</condition>
  <condition>Stress Ulcers</condition>
  <arm_group>
    <arm_group_label>Proton pump inhibitor (PPI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pantoprazole 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (0.9%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>40 mg x 1 daily intravenously from ICU admission to ICU discharge</description>
    <arm_group_label>Proton pump inhibitor (PPI)</arm_group_label>
    <other_name>Pantoloc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline (0.9%)</intervention_name>
    <description>10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Acute admission to the ICU

          -  Age ≥ 18 years

          -  One or more of the following risk factors:

               -  Shock (continuous infusion with vasopressors or inotropes, systolic blood
                  pressure &lt; 90 mmHg, mean arterial blood pressure &lt; 70 mmHg or lactate &gt; 4 mmol/l)

               -  Acute or chronic intermittent or continuous renal replacement therapy

               -  Invasive mechanical ventilation which is expected to last &gt; 24 hours

               -  Coagulopathy (platelets &lt; 50 x 109/l or international normalized ratio (INR) &gt;
                  1.5 or prothrombin time (PT) &gt; 20 seconds) documented within the last 24 hours

               -  Ongoing treatment with anticoagulant drugs (prophylaxis doses excluded)

               -  History of coagulopathy (platelets &lt; 50 x 109/l or INR &gt; 1.5 or PT &gt; 20 seconds)
                  within 6 months prior to hospital admission

               -  History of chronic liver disease (portal hypertension, cirrhosis proven by
                  biopsy, computed tomography (CT) scan or ultrasound, history of variceal bleeding
                  or hepatic encephalopathy in the past medical history)

        EXCLUSION CRITERIA:

          -  Contraindications to PPI

          -  Ongoing treatment with PPI and/or H2RA on a daily basis

          -  GI bleeding of any origin during current hospital admission

          -  Diagnosed with peptic ulcer during current hospital admission

          -  Organ transplant during current hospital admission

          -  Withdrawal from active therapy or brain death

          -  Fertile woman with positive urine human chorionic gonadotropin (hCG) or plasma-hCG

          -  Consent according to national regulations not obtainable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Hylander Møller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Perner, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Århus University Hospital Nørrebrogade</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Århus University Hospital Skejby</name>
      <address>
        <city>Arhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurointensive Care, Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Copenhagen University Hospital Herlev</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Herning Hospital</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Hillerød Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Hjørring Hospital</name>
      <address>
        <city>Hjørring</city>
        <zip>9800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Holbæk Hospital</name>
      <address>
        <city>Holbæk</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Holstebro Hospital</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Køge University Hospital</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Nykøbing Falster Sygehus</name>
      <address>
        <city>Nykøbing Falster</city>
        <zip>4800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Randers Hospital</name>
      <address>
        <city>Randers</city>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Heerlen Hospital</name>
      <address>
        <city>Heerlen</city>
        <zip>6419</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Bergen University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Basel University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.sup-icu.com</url>
    <description>SUP-ICU webpage</description>
  </link>
  <reference>
    <citation>Krag M, Perner A, Wetterslev J, Wise MP, Hylander Møller M. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014 Jan;40(1):11-22. doi: 10.1007/s00134-013-3125-3. Epub 2013 Oct 19. Review.</citation>
    <PMID>24141808</PMID>
  </reference>
  <reference>
    <citation>Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, McArthur C, Cook D, Nielsen N, Pelosi P, Keus F, Guttormsen AB, Moller AD, Møller MH; SUP-ICU co-authors. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med. 2015 May;41(5):833-45. doi: 10.1007/s00134-015-3725-1. Epub 2015 Apr 10.</citation>
    <PMID>25860444</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>January 21, 2018</last_update_submitted>
  <last_update_submitted_qc>January 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Scandinavian Critical Care Trials Group</investigator_affiliation>
    <investigator_full_name>Dr. Morten Hylander Møller</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Stress ulcer prophylaxis</keyword>
  <keyword>Proton pump inhibitor</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Clostridium difficile infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

